Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 09/16
116.4 HKD   -0.85%
04:32aHong Kong shares rebound, led by tech, healthcare
RE
12:53aShanghai stocks fall as coal shares drag; Hong Kong rebounds
RE
09/14Hong Kong shares end lower, dragged by property, financials and tech
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WuXi Biologics Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

07/13/2021 | 07:31pm EDT

WuXi Biologics (Cayman) Inc. provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, it is expected that the profit attributable to equity shareholders of the Company for the six months ended June 30, 2021 will increase more than 135% compared with the profit attributable to equity shareholders of the Company for the corresponding period of last year.


© S&P Capital IQ 2021
All news about WUXI BIOLOGICS (CAYMAN) INC.
04:32aHong Kong shares rebound, led by tech, healthcare
RE
12:53aShanghai stocks fall as coal shares drag; Hong Kong rebounds
RE
09/14Hong Kong shares end lower, dragged by property, financials and tech
RE
09/06Hong Kong shares rise, led by tech and financials
RE
09/01Hong Kong shares rise as tech, financial sectors gain
RE
09/01WuXi Biologics Received First Manufacturing License from Japan and Completed ..
CI
09/01China stocks gain as policy easing expectations rise; Hong Kong up
RE
08/24WUXI BIOLOGICS CAYMAN : Voluntary announcement - appointment of co-chief financi..
PU
08/24Wuxi Biologics Inc. Appoints Ming Tu as Executive Vice President
CI
08/24WuXi Biologics Inc. Announces Appointment of Ming Tu as Co-Chief Financial Of..
CI
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2021 9 581 M 1 485 M 1 485 M
Net income 2021 2 987 M 463 M 463 M
Net cash 2021 5 873 M 910 M 910 M
P/E ratio 2021 135x
Yield 2021 -
Capitalization 410 B 63 410 M 63 467 M
EV / Sales 2021 42,1x
EV / Sales 2022 28,5x
Nbr of Employees 7 686
Free-Float 84,3%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 96,59 CNY
Average target price 130,08 CNY
Spread / Average Target 34,7%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Chief Executive Officer & Executive Director
Shao Hua Lu-Wong Co-Chief Financial Officer
Ming Tu Co-Chief Financial Officer & Executive VP
Ge Li Non-Executive Chairman
Weichang Zhou Executive Director, Chief Technology Officer & EVP
Sector and Competitors